Assessment of Simvastatin Effect and Compare It's with Combination of Calcium plus Vitamin D3 in Postmenopausal Women with Osteoporosis

Abstract

In osteoporosis, bone strength declines, which increases the chance of bone loss, making
it a silent disease. In the elderly, it is the leading cause of bone loss. Forearms, hips, and
backbones are among the bones most prone to breaking. There are no symptoms until the
bones are destroyed. Bones eventually degenerate to the point that a fracture can occur
spontaneously or as a result of simple force. Even after the bone has been destroyed, patients
may still experience chronic discomfort and diminished mobility. The goal of this study was
to examine the effectiveness of simvastatin with calcium and vitamin D3 in treating
osteoporosis in postmenopausal women. Postmenopausal women suffering from bone loss
were separated into two groups of twelve women each, with a total of twenty four participants.
Twelve postmenopausal women who did not have osteoporosis were included as a control
group. Six months of treatment were required. One group took 20mg of simvastatin twice a
day, whereas the other took calcium and vitamin D3 (D3 500 I.U. plus 600mg of calcium)
twice a day. T-scores, BMD, triglycerides, and total cholesterol were measured in both groups
before and after treatment. Patients on simvastatin had significantly higher T-scores than those
in the control and calcium + vitamin D3 treatment groups after six months of treatment. After
six months of treatment, The simvastatin and calcium + vitamin D3 groups had significantly
lower mean serum triglyceride and total cholesterol levels than the control group.